NCT00303797View on ClinicalTrials.gov

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2010

Conditions

Refractory Chronic Lymphocytic LeukemiaRefractory Multiple MyelomaStage III Multiple MyelomaStage IV Chronic Lymphocytic LeukemiaUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

17-N-allylamino-17-demethoxygeldanamycin/bortezomib

DRUG

sorafenib tosylate

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00303797 - Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter